Menu
PacPremier
Magic Hour
Montecito
SoCal Gas
Loading...
You are here:  Home  >  'Humira'  -  Page 2
Latest

FDA gives big win to Amgen in biosimilars race

By   /  Friday, September 30th, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA gives big win to Amgen in biosimilars race

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

FDA approves Amgen biosimilar of AbbVie’s Humira

By   /  Friday, September 23rd, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA approves Amgen biosimilar of AbbVie’s Humira

The Food and Drug Administration approved Amgen’s Humira biosimilar Sept. 23. Amjevita, formerly known as ABP 501 and made by Thousand Oaks-biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based competitor AbbVie, typically costs $20,000 per year Read More →

Read More →
Latest

Abbvie sues Amgen to block sales of Humira biosimilar

By   /  Friday, August 5th, 2016  /  Central Coast Health Watch, Latest news, Law, Technology  /  Comments Off on Abbvie sues Amgen to block sales of Humira biosimilar

Thousand Oaks-based biotech giant Amgen faces a lawsuit seeking to block it from selling a biosimilar of AbbVie’s popular Humira. The rheumatoid arthritis medicine is Abbvie’s best seller. Sales were up 17 percent in the second quarter to $4.15 billion and accounted for 61 percent of AbbVie’s 2015 revenue. Abbvie claims Amgen’s proposed copy would Read More →

Read More →
Latest

Amgen wins one, loses one in biosimilar battle

By   /  Friday, July 15th, 2016  /  Central Coast Health Watch, East Ventura County, left, Technology  /  Comments Off on Amgen wins one, loses one in biosimilar battle

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

FDA panel recommends Amgen biosimilar drug for approval

By   /  Tuesday, July 12th, 2016  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on FDA panel recommends Amgen biosimilar drug for approval

A Food and Drug Administration panel recommended an Amgen biosimilar drug for approval July 12, just days after it said the biosimilar performed like a drug it mimicked. ABP 501, made by Thousand Oaks biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and Read More →

Read More →
Latest

FDA finds Amgen biosimilar replicates effects of Humira

By   /  Friday, July 8th, 2016  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on FDA finds Amgen biosimilar replicates effects of Humira

The Food and Drug Administration said a new Amgen biosimilar replicates the effects of a competitor’s blockbuster drug July 8. ABP 501 replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. The drug, made by Chicago-based competitor AbbVie, typically costs $20,000 per year for Read More →

Read More →
Latest

Amgen suffers setback as patent office refuses to review competitor’s drug

By   /  Thursday, January 14th, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on Amgen suffers setback as patent office refuses to review competitor’s drug

The U.S. Patent and Trademark Office handed Amgen a potential setback Jan. 14 when it declined to review two patent expiration dates on a competitor’s drug. In June, Thousand Oaks-based biotech giant Amgen asked the agency to review two formulation patents for Humira, made by Chicago-based competitor AbbVie, arguing that the patents should not have Read More →

Read More →